Skip to main content
main-content

Cardiovascular outcomes

01-12-2022 | Semaglutide | News

High-dose semaglutide reduces obesity-linked inflammatory marker

Levels of the inflammatory marker C-reactive protein decrease in people with or without type 2 diabetes taking weekly semaglutide 2.4 mg, shows analysis of three STEP trials.

Human kidney cross section

08-11-2022 | SGLT2 inhibitors | News

Meta-analysis backs SGLT2 inhibitors for kidney disease

A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.

07-11-2022 | Lipid-lowering medications | News

Pemafibrate disappoints in high-risk type 2 diabetes

Treatment with pemafibrate does not reduce the risk for cardiovascular events in people with type 2 diabetes, despite substantial reductions in triglycerides, report the PROMINENT trial investigators.

04-11-2022 | Empagliflozin | News | Article

EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease

Treating people with chronic kidney disease with the SGLT2 inhibitor empagliflozin significantly reduces their risk for renal disease progression or cardiovascular mortality, report the EMPA-KIDNEY investigators.

24-10-2022 | Cardiovascular outcomes | News

Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection

Age, duration of type 2 diabetes, and race may help guide choice of glucose-lowering therapy for individuals with established CVD or those at high risk, say the authors of a systematic review and meta-analysis published in eClinicalMedicine.

Cardiovascular event - symbolic image

21-10-2022 | Cardiovascular disorders | News

Diabetes ‘no longer a CVD risk equivalent’

The strength of the association between diabetes and the risk for cardiovascular events has lessened over recent years, report researchers.

13-10-2022 | Anti-hypertensive medications | News

TIME of antihypertensive administration ‘should be shared decision’

The TIME study finds no difference between morning and evening administration of antihypertensive medications in terms of preventing major adverse cardiovascular events.

Piggy bank balancing on seesaw over a bottle of pills

04-10-2022 | Healthcare costs | News

First-line SGLT2 inhibitors, GLP-1 receptor agonists ‘not cost effective’

The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.